NEW YORK (TheStreet) -- Bristol Myers Squibb (BMY) has been a stock that Jim and I have owned in the past and have been watching it as one to possibly own again. This morning it announced a $7.1 billion deal to acquire Amylin Pharmaceuticals (AMLN) as it tries to expand its diabetes franchise with partner AstraZeneca (AZN).
The deal is a smart one for many reasons - it expands its diabetes pipeline, shares the economic risk as AZN will payout $3.4 billion for a 50% share in the economics, and uses its cash ($8.6 billion in 1Q) wisely to build out its product franchise in the face of the Plavix patent cliff (which accounts for 30% of its revenues). Currently, BMY and AZN have a joint venture in diabetes with two drugs - Onglyza (which is on the market currently) and Dapagliflozin (yet to be approved by the FDA). The addition of Amylin's Byetta and Bydureon products could lead to an additional $1.5 billion in sales for this segment which could be as much as 12-20 cents accretive in 2016. It's not a layup to get to $1.5 billion in sales, but the growth in the diabetes market and the sales/marketing muscle behind BMY/AZN should make it doable.
We applaud management for building out its products and it now has one of the most diversified pipelines in the sector - cardiovascular diseases, virology, immunology, oncology, and central nervous system disorders. The only issue is that the stock is expensive - trading at 19x forward estimates which is a healthy premium to its 14x historical average and the 12.7x group average multiple. It has a great yield, a sizable buy back (it just announced a new $3 billion buy back last week) and is a defensive stock - which is attractive in this volatile macro environment. Usually when companies make acquisitions the acquirer shares typically fall - and sometimes an opportunity to buy. I doubt it will fall materially, but if it does, it's one on our radar to buy.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV